{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"6.8","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"16.6","value":"2.8"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"6.2","value":"1.4"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"5.5","value":"3.4"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"5.6","value":"1.4"},{"groupId":"OG005","lowerLimit":"1.2","upperLimit":"2.9","value":"1.4"},{"groupId":"OG006","lowerLimit":"1.3","upperLimit":"6.9","value":"1.4"},{"groupId":"OG008","lowerLimit":"1.1","upperLimit":"9.8","value":"1.4"},{"groupId":"OG009","lowerLimit":"1.2","upperLimit":"7.2","value":"1.4"},{"groupId":"OG010","lowerLimit":"1.1","upperLimit":"9.8","value":"1.4"},{"groupId":"OG011","lowerLimit":"1.2","upperLimit":"7.2","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"16"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"44"},{"groupId":"OG011","value":"41"}],"units":"Participants"}],"description":"Time between date of start of treatment until first documented response (confirmed CR or PR) per RECIST 1.1 by BIRC assessment.\n\nCR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","dispersionType":"Full Range","groups":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG000","title":"Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","id":"OG001","title":"Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG002","title":"Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG003","title":"Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG004","title":"Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","id":"OG005","title":"Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","id":"OG006","title":"Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","id":"OG007","title":"Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","id":"OG008","title":"Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","id":"OG009","title":"Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)"},{"description":"All pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L). (Participants from Cohort 4 and Cohort 6.2)","id":"OG010","title":"Cohort 4 + Cohort 6.2: All Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"All treatment naive patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as first line (1L) (Participants from Cohort 5b and Cohort 7)","id":"OG011","title":"Cohort 5b + Cohort 7: All Treatment-naive With MET Mutation Regardless of MET GCN (1L)"}],"paramType":"MEDIAN","populationDescription":"Participants with confirmed CR or PR by BIRC in FAS","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years","title":"Time to Response (TTR) by BIRC Assessment","type":"SECONDARY","unitOfMeasure":"Months"}